Vera's atacicept already hit its Phase 3 bar; 2027 readout tests durability
ORIGIN 3 met its week 36 proteinuria endpoint with a 42% placebo-adjusted UPCR reduction in 2025; the 2027 two-year data will show whether that benefit holds and whether kidney function follows.
Executive Summary
- ORIGIN 3 already met its primary endpoint in June 2025: a 42% placebo-adjusted UPCR reduction at week 36 (p<0.0001), the metric regulators use as a proteinuria surrogate in IgAN Press ReleasePress ReleaseJun 2, 2025. This is not an open binary; the result is disclosed and sourced to the sponsor's own press release.
- The two-year data due in 2027 will show whether that benefit is durable and, critically, will include eGFR (kidney function) results Vera withheld at FDA's own request while the placebo-controlled comparison continues Press ReleasePress ReleaseJun 2, 2025. That is the real information gap this catalyst closes.
- No AppliedXL Probability of Success model read exists for the 2027 readout in this seed; the dossier also carries no posted CT.gov results yet, so the durability call rests entirely on sponsor disclosure until the two-year data post.
- RemeGen's telitacicept and Alpine's povetacicept are direct BAFF-targeting comparators advancing in Phase 3 and Phase 1/2 IgAN respectively, and Novartis's zigakibart is running a Phase 3 APRIL-targeted program in the same indication. The durability data will be read against that field.
- The trial's primary completion date has moved four times, slipping from December 2022 to May 2025, a 29-month cumulative delay, with enrollment expanding from 105 to 376 along the way. That instability is a track-record flag for timing discipline, not a read on the disclosed efficacy result.
The disclosed result
Vera Therapeutics, Inc. announced on June 2, 2025 that ORIGIN 3, its Phase 3 trial of atacicept in IgA nephropathy (NCT04716231), met its primary endpoint Press ReleasePress ReleaseJun 2, 2025. Patients on atacicept saw a 46% reduction from baseline in 24-hour urine protein-to-creatinine ratio (UPCR), and a 42% reduction relative to placebo at week 36, with p<0.0001 Press ReleasePress ReleaseJun 2, 2025. Richard Lafayette, the trial's primary investigator, called it 'the first Phase 3 clinical trial in IgAN to demonstrate this magnitude of UPCR reduction compared to placebo at week 36' Press ReleasePress ReleaseJun 2, 2025. The safety profile was described as favorable and comparable to placebo Press ReleasePress ReleaseJun 2, 2025.
What's still missing
Vera did not disclose eGFR (estimated glomerular filtration rate, a kidney-function measure) results at week 36, stating it is withholding that data 'per FDA guidance' while the placebo-controlled portion of ORIGIN 3 continues Press ReleasePress ReleaseJun 2, 2025. eGFR change is the harder outcome regulators and competitors weigh for a full, rather than accelerated, approval case in IgAN. The two-year results expected in 2027 are where that gap gets filled, alongside confirmation that the week 36 proteinuria benefit does not narrow over time.
Regulatory posture
Atacicept holds FDA Breakthrough Therapy Designation, first granted based on Phase 2b ORIGIN data in mid-2024 and reaffirmed after the Phase 3 result. Vera said it planned to submit a Biologics License Application for accelerated approval in the fourth quarter of 2025, targeting a 2026 launch if cleared Press ReleasePress ReleaseJun 2, 2025. An accelerated approval built on the UPCR surrogate would carry a mandatory confirmatory-trial obligation, and the two-year ORIGIN 3 data are the most direct candidate to satisfy that requirement.
Competitive field
Atacicept is not the only BAFF-targeting asset moving through IgAN development. RemeGen's telitacicept (NCT05799287) is in Phase 3 with an identical BAFF target and protein-therapy modality, and Alpine Immune Sciences' povetacicept (NCT05732402) targets BAFF in Phase 1/2. Novartis's zigakibart (NCT06858319) is a Phase 3 APRIL-targeted monoclonal antibody, a related but mechanistically distinct approach that is not a direct comparator to atacicept's dual BAFF/APRIL inhibition. The field carries a moderate landscape score of 49 with 8 active trials and 1,368 total enrolled patients, giving the 2027 durability data a competitive backdrop rather than a vacuum.
Timing discipline
ORIGIN 3's primary completion date moved four times: from December 2022 to March 2023, then to June 2025, then to May 2025, then to May 15, 2025, a cumulative slip of 29 months from the original target. Enrollment grew from 105 to a peak of 492 before settling at 376, a change pattern the registry-based protocol-stability tool rates 'Moderate' with 2.4 changes per year. None of this bears on the disclosed efficacy result, but it is a track record investors should weigh when judging whether the 2027 window holds without further slippage.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.